Jammu, June 6 -- In a remarkable academic milestone for Indian dermatology, Dr. Mir Shahnawaz, a leading dermatologist and Founder & Director of DERMIS Skin & Hair Clinic, Bemina, has earned international acclaim with the publication of his groundbreaking research in the CUREUS Journal, a globally recognized, PubMed-indexed platform under Springer.
Titled "Clinical Assessment of Abrocitinib, Tofacitinib, and Cyclosporine in Adult Patients With Moderate to Severe Atopic Dermatitis: A Retrospective Analysis," the study represents the first comparative real-world clinical research from India to evaluate these three systemic therapies, including Abrocitinib, a novel selective JAK-1 inhibitor.Click Here To Follow Our WhatsApp Channel
Dr. Sha...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.